Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447123 | 1.00 | AVPR2 (0.68) | AVPR2AVPR1A | |
| SCHEMBL3447121 | 1.00 | AVPR2 (0.68) | AVPR2AVPR1A | |
| SCHEMBL3448385 | 0.89 | AVPR2 (0.64) | AVPR2AVPR1A | |
| SCHEMBL19265280 | 0.88 | AVPR2 (0.61) | AVPR2AVPR1A | |
| SCHEMBL717216 | 0.88 | AVPR2 (0.65) | AVPR2AVPR1A | |
| SCHEMBL19244842 | 0.87 | AVPR2 (0.64) | AVPR2AVPR1A | |
| SCHEMBL3446952 | 0.87 | AVPR2 (0.72) | AVPR2AVPR1A | |
| SCHEMBL3446947 | 0.87 | AVPR2 (0.72) | AVPR2AVPR1A | |
| SCHEMBL3446949 | 0.87 | AVPR2 (0.72) | AVPR2AVPR1A | |
| SCHEMBL719175 | 0.85 | AVPR2 (0.62) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | AVPR2 2370/4885AVPR1A 3230/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | AVPR2 2370/4885AVPR1A 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.